OptimizeRx (OPRX) to Release Earnings on Wednesday

OptimizeRx (NASDAQ:OPRX) will likely be releasing its earnings data after the market closes on Wednesday, March 26th. Analysts expect OptimizeRx to post earnings of $0.27 per share and revenue of $30.36 million for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

OptimizeRx Stock Up 4.3 %

Shares of NASDAQ:OPRX opened at $9.00 on Tuesday. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $14.13. The stock’s 50-day moving average price is $5.92 and its two-hundred day moving average price is $5.93. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 0.29. The firm has a market cap of $165.79 million, a price-to-earnings ratio of -6.77 and a beta of 1.31.

Insider Activity at OptimizeRx

In related news, Director James Paul Lang purchased 321,408 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the acquisition, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. The trade was a 472.35 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 6.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the stock. Lake Street Capital restated a “buy” rating and issued a $11.00 target price on shares of OptimizeRx in a report on Tuesday, December 24th. JMP Securities reissued a “market outperform” rating and set a $8.00 price objective on shares of OptimizeRx in a research note on Thursday, February 6th. B. Riley raised OptimizeRx to a “strong-buy” rating in a research report on Wednesday, March 12th. Royal Bank of Canada reissued a “sector perform” rating and set a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a research report on Wednesday, January 8th. Finally, Stephens began coverage on OptimizeRx in a research note on Friday, December 20th. They set an “equal weight” rating and a $5.50 price target for the company. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, OptimizeRx has a consensus rating of “Moderate Buy” and an average price target of $9.06.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.